Prostate Cancer Rates Climb Again After A Decade Of Decline: 80% Of Americans Don’t Know Early Stage Disease Has No Symptoms

Prostate cancer deaths in the United States were on the decline, thanks to advances in screening and treatment but new data from the American Cancer Society (ACS) shows that the tide is shifting — prostate cancer rates have been climbing steadily for the past decade, particularly in advanced stages of the disease. At the same time, a new national survey highlights a troubling gap in public awareness, 80% of Americans don’t know that early-stage prostate cancer often has no symptoms, underscoring why early detection remains such a challenge.According to the ACS’s latest prostate cancer statistics report, diagnoses of prostate cancer have increased by about 3% per year since 2014. This rise is particularly striking given that the decade before saw a 6.4% annual decline. What is most concerning is not only that more men are being diagnosed, but that more cases are being caught at advanced stages. The report notes that advanced-stage diagnoses are climbing at an even faster rate — up to 6.2% annually, depending on the age group.Mortality trends add another layer of concern. In the 1990s and 2000s, prostate cancer death rates declined by 3% to 4% per year. Over the past decade, however, that rate of decline has slowed dramatically to just 0.6% annually.Why is Prostate Cancer Screening Still Debatable?One reason for the reversal may lie in the U.S. Preventive Services Task Force’s (USPSTF) guidance from the early 2010s, which advised against routine prostate-specific antigen (PSA) screening. The goal was to reduce overdiagnosis and overtreatment, as PSA testing can detect cancers that are slow-growing and unlikely to ever cause harm.But the shift away from routine screening may have had unintended consequences. With fewer men undergoing PSA tests, cancers are now being discovered later and at more aggressive stages. “We actually see PSA testing this decade versus the previous decade going down, so the incidence [of prostate cancer] is going up despite less testing occurring,” experts from ACS noted. “That starts to speak to other factors that might be environmental or nutritional or other things that we don’t fully understand.”The paradox is clear: cutting back on PSA tests may have reduced overdiagnosis, but it may also be fueling the resurgence of advanced-stage disease.Why Are Americans in the Dark About Prostate Cancer Detection?Compounding the problem is public misunderstanding of prostate cancer symptoms. A nationwide survey conducted by The Ohio State University Comprehensive Cancer Center revealed that four out of five Americans don’t know early-stage prostate cancer often has no symptoms at all. Most cases are detected only through routine screening, usually via a blood test for PSA levels.The survey also found that 59% of respondents did not know sexual dysfunction can be a warning sign. Often, it’s partners who first notice these changes and encourage men to seek medical care. Other lesser-known symptoms — such as fatigue or unexplained weight loss — were better recognized by Black adults than by white adults, but Black respondents were less likely to know that early-stage disease can be asymptomatic.This knowledge gap matters. When men assume they’ll feel ill if something is wrong, they’re less likely to prioritize regular screenings.The ACS report also highlights stark racial disparities. Black men are twice as likely to die from prostate cancer as men from any other racial or ethnic group. Native American men, meanwhile, have a 12% higher death rate compared to white men despite a 13% lower incidence of the disease.The reasons for these disparities are complex, involving a mix of biology, access to care, socioeconomic factors, and structural inequities in healthcare. What remains clear is that certain populations are paying a higher price for gaps in screening and treatment access.Most common cancer in US men, Prostate cancer accounts for about 30% of male cancer diagnoses in 2025. Second leading cause of cancer death: After lung cancer, prostate cancer kills nearly 36,000 men annually in the U.S.Annual cases: More than 300,000 American men are expected to be diagnosed in 2025.Age factor: The majority of cases occur in men over 50.Why Is Prostate Cancer Screening Crucial?While the debate over PSA testing continues, experts agree on one point: men need to have informed conversations with their doctors about screening. The ACS and other organizations recommend that men aged 45 and older talk with their healthcare providers about the benefits and risks. For those at higher risk including Black men and those with a family history of prostate cancer — those discussions should begin as early as age 40.Screening can be a double-edged sword. It may detect cancers that grow slowly and never cause harm, but it can also catch aggressive cancers before they spread. Without it, many men may not realize they’re sick until it’s too late for curative treatment.Ohio State Cancer Center patient Daryl Wilber and his wife, Jodi, were shocked when a routine blood test revealed he had early-stage prostate cancer. He had no symptoms. For Jodi, the lesson is clear: partners play a vital role in men’s health. “Help them get over that hump from going from ‘Yeah, yeah, yeah, I know I should do it’ to, ‘OK, I’m going to go tomorrow and do it,’” she said.Their story echoes what oncologists stress — early detection saves lives. Because prostate cancer often progresses slowly, finding it early greatly improves survival odds.What are The Pros and Cons of Screening?PSA testing and digital rectal exams remain the two primary tools for early detection. But both come with limitations. Elevated PSA doesn’t always mean cancer, and not all prostate cancers need immediate treatment. Some may never grow large enough to cause harm, leading to unnecessary treatments that carry risks such as urinary incontinence and erectile dysfunction.That’s why many doctors recommend “shared decision-making”, weighing the risks and benefits together with the patient. Screening is not a one-size-fits-all solution. The right approach depends on age, race, family history, and personal health values.The ACS projects nearly 314,000 new prostate cancer cases in 2025. That number, coupled with the slowed progress in reducing mortality, signals a pressing need to rethink screening strategies and public education.Too many men and their families still believe symptoms will be obvious. Too many assume prostate cancer is always slow-growing. And too many at-risk populations lack access to timely testing and care.

Prostate Cancer Rates Climb Again After A Decade Of Decline: 80% Of Americans Don’t Know Early Stage Disease Has No Symptoms

Quick Stories

Best Sleeping Position for Back Pain Relief: How To Wake Up Without Aches or Stiffness

What Doctors Thought Was A Sports Injury Turned Out To Be A Rare Form Of Cancer For This Teenager

COVID Symptoms Are Different In 2025—How Long After Exposure Should You Get Tested?

Health Conditions A-Z

Your Daily Dose Of Caffeine May Make Antibiotics Less Effective, Study Warns

Best Sleeping Position for Back Pain Relief: How To Wake Up Without Aches or Stiffness

Artificial Sweeteners Could Accelerate Brain Decline By 1.5 Years, Study Finds